Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients.

@article{Heffron2007OncedailyTE,
  title={Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients.},
  author={Thomas G Heffron and Mark D. Pescovitz and Sandy Florman and Munci Kalayoglu and Sukru H. Emre and Gregory Smallwood and Kathleen Wisemandle and Caterina Anania and Shobha S Dhadda and Taiji Sawamoto and James J. Keirns and William E. Fitzsimmons and M. Roy First},
  journal={American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons},
  year={2007},
  volume={7 6},
  pages={1609-15}
}
The pharmacokinetics, safety and tolerability of a once-daily formulation of tacrolimus (tacrolimus extended-release formulation; XL formerly referred to as MR or MR4) were assessed in 18 stable pediatric liver transplant recipients who were converted from the twice-a-day formulation of tacrolimus (TAC) to XL. Patients received their twice-a-day dose of TAC on study days 1 through 7. Beginning on the morning of study day 8, patients were converted to XL on a 1:1 (mg:mg) basis for their total… CONTINUE READING